World Vaccine Congress 2015: Industry Insights

The World Vaccine Congress  is the  premier event in the vaccine calendar. It is the place where the vaccine industry meets to discuss scientific and commercial issues around vaccine research, development, manufacture and distribution. With only seven weeks to go till the event, we’re getting pretty excited and we hope you are too!  We’ve been in touch with a few of our …

New uses for Cord Blood as an immunotherapy - will be covered at the Cord Blood World Europe Congress, 20-21 May in London at the Business Design Centre

New uses for Cord Blood as an immunotherapy and in the treatment of lysosomal storage disease

Dr Jaap Boelens, Pediatric Oncologist at the University of Utrecht has also been working on developing multiple treatments using cord blood. One of which involves using cord blood transplants to improve the outcomes of an immunotherapy (Dendritic Cell Vaccination) which will go into the clinic later this year. He will be discussing his findings at the Cord Blood World Europe Congress in …

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Download: The role of big pharma interview with Rino Rappuoli

What is the role of big pharma? This is what we asked Dr Rino Rappuoli, Global Head of Vaccines Research, Novartis Vaccines and Diagnostics in our series Vaccine Viewpoints. “How do you feel the role of big pharma is going to change in the vaccine industry in the coming year, and what are Novartis doing to ensure continuing success? Overall, I think companies …

Global Green Vs. Salmonella

Salmonella causes about 1.2 million cases of food poisoning each year. Its victims are most likely to be 5 or younger, adults older than 65, and individuals with impaired immune systems. Infections from Salmonella, which can be deadly, result in $365 million in direct medical costs each year, according to the CDC.   Download Global Green’s whitepaper to read more …

Nuron Biotech has licensed a gene-based amyloid beta 42 (Aβ42) #vaccine

Nuron Biotech has licensed from Vitruvian BioMedical a gene-based amyloid beta 42 (Aβ42) vaccine that is in preclinical development for Alzheimer disease. The vaccine contains a piece of the gene coding for the amyloid beta protein and works by stimulating an immune response where antibodies are produced which bind to and reduce amyloid beta. Under the agreement, Nuron is responsible …